Navigation Links
Pharsight Achieves First License Sale for Public-Source Database
Date:8/27/2007

Global Biotechnology Company Licenses Pharsight's Diabetes Meta-Database to

Quantify Competitive Treatment Landscape and Accelerate Model-Based

Decision-Making

MOUNTAIN VIEW, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has licensed its public-source Type II Diabetes meta-database to a global biotechnology company. The licensee plans to use the database to build quantitative models of the competitive landscape for oral diabetes treatments that will help inform clinical program decision-making for promising compounds in its diabetes pipeline. This is the first license Pharsight has sold for one of its 20 available meta-databases.

Pharsight's meta-database for Type II Non-Insulin Dependent Diabetes Mellitus (NIDDM) captures clinical efficacy and safety measures from 106 clinical trials, including multiple drug classes and comparative treatments and more than 30 clinical endpoints. Pharsight's meta-databases cover specific disease areas and have been assembled by a team of clinical database and clinical pharmacy experts dedicated to extracting information from the public domain and transforming this information into model-ready datasets.

"Clients use such a meta-database to compare the simulated efficacy and safety of candidate drugs they are developing to the established efficacy and safety of competing drugs," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "This provides an improved understanding of the clinical potential of a drug candidate and earlier assessment of competitive viability, which could lead to faster, more confident decisions to invest or disinvest. Pharsight is pleased to offer public-source clinical databases, many in high-prevalence disease areas, to further enable efficient drug-disease modeling and support our client's critical drug development decisions."

About Pharsight Public-Source Meta-databases

Pharsight meta-databases provide highly structured quantitative information from the public-source scientific literature that can be used to understand the competitive landscape for a particular therapeutic area and indication. Meta-databases provide a publicly available starting point for model-based drug development approaches, often combining proprietary data on a specific compound with literature data of its likely competitors, to manage risk and address specific drug development program questions concerning dose selection, efficient and effective trial design, and "go/no-go" decisions. Pharsight offers meta-databases in nine therapeutic areas, covering 20 disease indications. Additional information is available at http://www.pharsight.com/services/scs_home.php.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Forward Looking Statements

The statements in this press release related to the design and performance of the Pharsight public-source meta-database offering are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for the product; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Inacom Information Systems achieves Cisco Systems Partner -Gold Certified status
2. Third Wave Achieves Milestone, Delivers 200,000 SNP Assays to RIKEN In Japan
3. The Genesis of Gendicine: The Story Behind the First Gene Therapy
4. Midwest life science stocks sizzle in a tepid first quarter
5. Morgridge Institute for Research seeks first CEO
6. Sonic Foundry reports first cash-positive quarter
7. Angel investors commit $12.7B in first half of `06
8. Aurora team implants Wisconsins first total artificial heart
9. First half of 2006 roundup: Big Pharma trumps biotech
10. GE announces first installation of Discovery VCT
11. GE Healthcare enjoys robust growth in first quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced ... the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to ... heard throughout the drug regulatory review process. , “Adding Diane Dorman is just ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists and  ... Experiences SHPG ) ... of children born with rare diseases, as well as the future ... a new initiative designed to positively affect the lives of children ... disease care. --> To mark the company,s founding 30 ...
(Date:2/8/2016)... 2016 Should antibiotic bone cement products be ... prevent infection after standard total hip or knee replacement ... Institute have been fielding a lot lately. ... Line?" --> "Antibiotic Bone Cement: ... --> While there isn,t a simple answer, ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas J. Todorow has joined ... President for Corporate Services and the Chief Financial Officer at The Children’s Hospital ... Treasury, Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP ...
Breaking Biology Technology:
(Date:2/3/2016)... February 3, 2016 --> ... research report "Automated Fingerprint Identification System Market by Component ... Application (Banking & Finance, Government, Healthcare, and Transportation) and ... the market is expected to be worth USD 8.49 ... between 2015 and 2020. The transformation and technology evolution ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):